Poltreg S.A. (PTG.WA)
PLN 40.0
(-7.83%)
PLN 40.0
(-7.83%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.19 Million PLN | 3.73% |
| 2022 | 7.89 Million PLN | 4337.64% |
| 2021 | 178 Thousand PLN | -76.67% |
| 2020 | 763 Thousand PLN | -62.6% |
| 2019 | 2.04 Million PLN | -49.93% |
| 2018 | 4.07 Million PLN | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 7.97 Million PLN | -0.44% |
| 2024 Q1 | 8.01 Million PLN | -2.21% |
| 2023 Q1 | 8.07 Million PLN | 2.28% |
| 2023 FY | 8.19 Million PLN | 3.73% |
| 2023 Q2 | 7.89 Million PLN | -2.29% |
| 2023 Q4 | 8.19 Million PLN | -7.22% |
| 2023 Q3 | 8.83 Million PLN | 11.88% |
| 2022 Q2 | 104 Thousand PLN | -26.24% |
| 2022 Q1 | 141 Thousand PLN | -20.79% |
| 2022 Q3 | 8.02 Million PLN | 7613.46% |
| 2022 FY | 7.89 Million PLN | 4337.64% |
| 2022 Q4 | 7.89 Million PLN | -1.53% |
| 2021 Q1 | 707 Thousand PLN | -7.34% |
| 2021 Q4 | 178 Thousand PLN | -22.27% |
| 2021 Q3 | 229 Thousand PLN | -16.12% |
| 2021 FY | 178 Thousand PLN | -76.67% |
| 2021 Q2 | 273 Thousand PLN | -61.39% |
| 2020 Q4 | 763 Thousand PLN | 0.0% |
| 2020 FY | 763 Thousand PLN | -62.6% |
| 2020 Q1 | - PLN | 0.0% |
| 2019 FY | 2.04 Million PLN | -49.93% |
| 2018 FY | 4.07 Million PLN | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioceltix S.A. | 175.05 Thousand PLN | -4580.761% |
| BIOTON S.A. | 68.69 Million PLN | 88.072% |
| Captor Therapeutics Spolka Akcyjna | 3.77 Million PLN | -116.887% |
| Mabion S.A. | 35.82 Million PLN | 77.13% |
| Molecure S.A. | 7.13 Million PLN | -14.772% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 181 Thousand PLN | -4427.072% |
| Pure Biologics Spólka Akcyjna | 12.93 Million PLN | 36.667% |
| Ryvu Therapeutics S.A. | 906 Thousand PLN | -804.415% |
| Synthaverse S.A. | 70.04 Million PLN | 88.301% |
| Urteste S.A. | 627 Thousand PLN | -1206.858% |